[1]石丽娟,李丽,石福艳,等.基于倾向性评分逆概率加权法的脉络膜黑色素瘤患者疗效评价研究[J].眼科新进展,2023,43(4):308-312.[doi:10.13389/j.cnki.rao.2023.0063]
　SHI Lijuan,LI Li,SHI Fuyan,et al.Efficacy evaluation of choroidal melanoma based on propensity score inverse probability of treatment weighting method[J].Recent Advances in Ophthalmology,2023,43(4):308-312.[doi:10.13389/j.cnki.rao.2023.0063]
点击复制

基于倾向性评分逆概率加权法的脉络膜黑色素瘤患者疗效评价研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
43卷
期数:
2023年4期
页码:
308-312
栏目:
应用研究
出版日期:
2023-04-05

文章信息/Info

Title:
Efficacy evaluation of choroidal melanoma based on propensity score inverse probability of treatment weighting method
作者:
石丽娟; 李丽; 石福艳; 周希彬; 吴志鸿
261053　山东省潍坊市，潍坊医学院临床医学院眼科学教研室（石丽娟，李丽）；100039　北京市，解放军总医院第三医学中心眼科医学部（石丽娟，李丽，周希彬，吴志鸿）；261053　山东省潍坊市，潍坊医学院公共卫生学院卫生统计学教研室（石福艳）
Author(s):
SHI Lijuan1; 2; LI Li1; 2; SHI Fuyan3; ZHOU Xibin2; WU Zhihong2
1.Department of Ophthalmology,School of Clinical Medicine,Weifang Medical University，Weifang 261053,Shandong Province，China
2.Senior Department of Ophthalmology,the Third Medical Center of PLA General Hospital,Beijing 100039,China
3.Department of Health Statistics,School of Public Health,Weifang Medical University,Weifang 261053,Shandong Province，China
关键词:
脉络膜黑色素瘤; 逆概率加权; 疗效; 生存分析
Keywords:
choroidal melanoma;  inverse probability of treatment weighting;  efficacy;  survival analysis
分类号:
R773.4
DOI:
10.13389/j.cnki.rao.2023.0063
文献标志码:
A
摘要:
目的　在平衡组间基线变量后，评价放射治疗与手术联合放射治疗两种治疗方式对脉络膜黑色素瘤患者的疗效，分析脉络膜黑色素瘤患者的预后影响因素，为脉络膜黑色素瘤的有效诊疗提供参考依据。
方法　对2000年1月至2019年12月在SEER数据库中登记的脉络膜黑色素瘤患者进行分析， 采用倾向性评分逆概率加权法（IPTW）对放射治疗和手术联合放射治疗两组患者的基线特征进行平衡。
结果　本研究共筛选脉络膜黑色素瘤患者5547例，其中接受放射治疗者4422例、接受手术联合放射治疗治疗者1125例。在接受放射治疗的4422例患者中，光束辐射（BR）组1155例，放射性植入物（RI）组2608例，放射性同位素（RIT）组659例。Log-rank检验结果显示，逆概率加权前后，放射治疗组患者的预后均高于手术联合放射治疗组（P<0.000 1）。多因素Cox回归分析结果显示，在控制了种族、性别、多灶性、是否为首要恶性肿瘤、婚姻状态、从诊断到治疗的时间、年龄、眼别、诊断确认、放射治疗方法等混杂因素后，与放射治疗组患者相比，手术放射治疗组患者的特异性死亡风险为HR=4.385（95%CI=3.542~5.428）。与年龄<50岁组患者相比，50~<60岁组、60~<70岁组、70~<80岁组、≥80岁组患者的特异性死亡风险分别为HR=3.083（95%CI=0.825~4.238）、HR=4.045（95%CI=2.955~5.532）、HR=4.512（95%CI=3.115~6.529）、HR=6.877（95%CI=4.151~11.398）；与恶性肿瘤数为1个组患者相比，肿瘤数为2个组和>2个组患者的特异性死亡风险分别为HR=0.698（95%CI=0.449~2.944）、HR=0.538（95%CI=0.317~0.913）；从诊断到治疗的时间超过1个月的患者的风险比为 2.732~ 4.154。Log-rank检验结果表明，IPTW前后BR、RI和RIT三组脉络膜黑色素瘤患者生存曲线间差异无统计学意义( P>0.05)。
结论　放射治疗的长期疗效优于手术与放射治疗联合治疗；年龄、单病灶、诊断到治疗的时间和治疗方式可增加脉络膜黑色素瘤患者死亡的风险，是影响脉络膜黑色素瘤患者预后的独立影响因素。
Abstract:
Objective　To evaluate the efficacy of radiotherapy and surgery combined with radiotherapy on choroidal melanoma and analyze the prognostic factors of choroidal melanoma upon balancing the inter-group baseline variables, giving a reference for effective diagnosis and treatment of choroidal melanoma.
Methods　Patients with choroidal melanoma enrolled from the Surveillance, Epidemiology, and End Results database from January 2000 to December 2019 were analy zed. Propensity score inverse probability of treatment weighting (IPTW) was used to balance the baseline characteristics of patients in the radiotherapy group and combined surgery and radiotherapy group.
Results　A total of 5547 patientswith choroidal melanoma were selected in this study, including 4422 patients who received radiotherapy and 1125 patients who received surgery combined with radiotherapy. Among the 4422 patients who received radiotherapy, 1155 were divided into the radioactive beam irradiation (BR) sub-group, 2608 were divided into the radioactive implant (RI) sub-group, and 659 were divided into the radioactive isotope (RIT) sub-group. The log-rank test showed that before and after IPTW, the prognosis of patients in the radiotherapy group was higher than that in the combined surgery and radiotherapy group (both P<0.000 1). The multivariate Cox regression analysis showed that after controlling the confounding factors such as race, gender, multifocality, primary malignant tumor, marital status, time from diagnosis to treatment, age, eye side, diagnosis confirmation and radiotherapy method, compared to patients in the radiotherapy group, the specific mortality risk in the combined surgery and radiotherapy group was HR=4.385 (95% CI=3.542-5.428). Compared to patients under 50 years old, the specific mortality risk of patients aged 50-59 years, 60-69 years, 70-79 years and ≥80 years was HR=3.083 (95% CI=0.825-4.238), HR=4.045 (95% CI=2.955-5.532), HR=4.512 (95% CI=3.115-6.529), and HR=6.877 (95% CI=4.151-11.398), respectively. Compared to patients with only 1 malignant tumor, the specific mortality risk of patients with 2 and more than 2 malignant tumors was HR=0.698 (95% CI=0.449-2.944) and HR=0.538 (95% CI=0.317-0.913), respectively. Patients who waited longer than one month from diagnosis to treatment had a risk ratio of 2.732 to 4.154. The log-rank test results showed no significant difference in the survival curves of patients in the BR, RI and RIT sub-groups of the radiotherapy group before and after IPTW (all P>0.05).
Conclusion　The long-term efficacy of radiotherapy is better than that of surgery combined with radiotherapy. Age, single lesion, time from diagnosis to treatment, and treatment methods, which can increase the risk of death in patients with choroidal melanoma, are independent influencing factors on the prognosis of choroidal melanoma patients.

参考文献/References:

［1］　KRUPKA A K,BUGAJ A M,LATOS W,ZAREMBA K,SIERON A.Photodynamic therapy in treatment of cutaneous and choroidal melanoma［J］.Photodiagnosis Photodyn Ther,2013,10(4):503-509.
［2］　HAMZA H S,ELHUSSEINY A M.Choroidal melanoma resection［J］.Middle East Afr J Ophthalmol,2018,25(2):65-70.
［3］　QUILES B,MATAIX J,GUINOT J L,WANG I,DOLORES L D V,PENA M,et al.Choroidal melanoma with Ultrasound-Guided episcleral brachytherapy:long-term results and risk of metastasis［J］.Ocul Oncol Pathol,2021,7(4):280-286.
［4］　EIBENBERGER K,DUNAVOELGYI R,GLEISSl A,SEDOVA A,GEORG D,POETTER R,et al.Hypofractionated stereotactic photon radiotherapy of choroidal melanoma:20-year experience［J］.Acta Oncol,2021,60(2):207-214.
［5］　DAMATO B,ELEUTERI A,FISHER A C,COUPLAND S E,TAKTAK A F.Artificial neural networks estimating survival probability after treatment of choroidal melanoma［J］.Ophthalmology,2008,115(9):1598-1607.
［6］　DAMATO B,ELEUTERI A,TAKTAK A F,COUPLAND S E.Estimating prognosis for survival after treatment of choroidal melanoma［J］.Prog Retin Eye Res,2011,30(5):285-295.
［7］　ZHANG Y S,HU T C,YE Y C,HAN J H,LI X J,ZHANG Y H,et al.Carbon ion radiotherapy for synchronous choroidal melanoma and lung cancer:a case report［J］.World J Clin Cases,2021,9(33):10374-10381.
［8］　杨津,柳青青,耿辉,田国祥,曾宪涛,吕军.SEER数据库的申请及数据提取方法与流程［J］.中国循证心血管医学杂志,2018,10(7):781-784.
YANG J,LIU Q Q,GEN G H,TIAN G X,ZENG X T,L J.SEER database application and data extraction method and process［J］.Chin J Evidence-Based Cardiovascular Medicine,2018,10(7):781-784.
［9］　SHI F Y,WANG C,KONG Y J,YANG L P,LI J,ZHU G P,et al.Assessing the survival benefit of surgery and various types of radiation therapy for treatment of hepatocellular carcinoma:evidence from the surveillance,epidemiology,and end results registries［J］.J Hepatocell Carcinoma,2020,7:201-218.
［10］　SINGH A D,TURELL M E,TOPHAM A K.Uveal melanoma:trends in incidence,treatment,and survival［J］.Ophthalmology,2011,118(9):1881-1885.
［11］　CHANG M Y,MCCANNEL T A.Local treatment failure after globe-conserving therapy for choroidal melanoma［J］.Br J Ophthalmol,2013,97(7):804-811.
［12］　GHASSEMI F,SHEIBANI S,ARJMAND M,POORBAYGI H,KOUHESTANI E,SABOUR S,et al.Comparison of lodide-125 and ruthenium-106 brachytherapy in the treatment of choroidal melanomas［J］.Clin Ophthalmol,2020,14:339-346.
［13］　KARIMI S,ARABI A,SIAVASHPOUR Z,SHAHRAKI T,ANSARI I.Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma:a systematic review and meta-analysis［J］.J Contemp Brachytherapy,2021,13(3):358-364.
［14］　王光璐,魏文斌,蔡善钰,卢凤才,马凯,李斌.脉络膜黑色素瘤敷贴放射治疗的初步观察［J］.中华眼底病杂志,2006(3):157-160.
WANG G L,WEI W B,CAI S Y,LU F C,MA K,LI B.Preliminary observation of radiotherapy for choroidal melanoma.［J］.Chin J Fundus Dis,2006(3):157-160.
［15］　梁建宏,黎晓新,姜燕荣.脉络膜黑色素瘤眼球保留治疗结果初步观察［J］.中华眼底病杂志,2006(3):150-153.
LIANG J H,LI X X,JIANG Y R.Preliminary observation on the results of eye sparing therapy for choroidal melanoma［J］.Chin J Fundus Dis,2006(3):150-153.
［16］　CHATTOPADHYAY C,KIM D W,GOMBOS D S,OBA J,QIN Y,WILLIAMS M D,et al.Uveal melanoma:from diagnosis to treatment and the science in between［J］.Cancer,2016,122(15):2299-2312.
［17］　DAMATO B E,HEIMANN H,KALIRAI H,COUPLAND S E.Age,survival predictors,and metastatic death in patients with choroidal melanoma:tentative evidence of a therapeutic effect on survival［J］.JAMA Ophthalmol,2014,132(5):605-613.
［18］　DOGRUSOZ M,JAGER M J,DAMATO B.Uveal melanoma treatment and prognostication［J］.Asia Pac J Ophthalmol(Phila),2017,6(2):186-196.
［19］　FALLON S J,SHIELDS C N,NICOLA M D.Trifocal choroidal melanoma in an eye with oculodermal melanocytosis:a case report［J］.Indian J Ophthalmol,2019,67(12):2092-2094.
［20］　Coupland S E,CAMPBELL I,DAMATO B.Routes of extraocular extension of uveal melanoma:risk factors and influence on survival probability［J］.Ophthalmology,2008,115(10):1778-1785.
［21］　DAMATO B,DUKE C,COUPLAND S E,HISCOTT P,SMITH A P,CAMPBELL L,et al.Cytogenetics of uveal melanoma:a 7-year clinical experience［J］.Ophthalmology,2007,114(10):1925-1931.

相似文献/References:

[1]高文,何彦津.姜黄素对人脉络膜黑色素瘤细胞株OCM-1血管生成拟态形态学和病理改变的影响[J].眼科新进展,2017,37(1):027.[doi:10.13389/j.cnki.rao.2017.0007]
　GAO Wen,HE Yan-Jin.Effects of curcumin on pathological and morphological changes of vasculogenic mimicry in choroid melanoma cell line OCM-1[J].Recent Advances in Ophthalmology,2017,37(4):027.[doi:10.13389/j.cnki.rao.2017.0007]
[2]高敏,唐金华,刘海芸.超声造影对兔眼脉络膜黑色素瘤血流循环的定量评估[J].眼科新进展,2017,37(11):1005.[doi:10.13389/j.cnki.rao.2017.0255]
　GAO Min,TANG Jin-Hua,LIU Hai-Yun.Quantitative evaluation of microcirculation in choroidal melanoma of rabbits using contrast-enhanced ultrasound[J].Recent Advances in Ophthalmology,2017,37(4):1005.[doi:10.13389/j.cnki.rao.2017.0255]
[3]高文,陈陆霞,何彦津,等.姜黄素对人脉络膜黑色素瘤细胞株血管形成拟态抑制作用及其相关机制的研究[J].眼科新进展,2017,37(11):1018.[doi:10.13389/j.cnki.rao.2017.0258]
　GAO Wen,CHEN Lu-Xia,HE Yan-Jin,et al.Inhibitory effects of curcumin on vasculogenic mimicry in choroid melanoma cell line OCM-1 and its mechanisms[J].Recent Advances in Ophthalmology,2017,37(4):1018.[doi:10.13389/j.cnki.rao.2017.0258]
[4]任耘,蔡明高,霍鸣.胰岛素样生长因子1受体（IGF-1R）基因表达对脉络膜黑色素瘤细胞增殖、凋亡及STAT3信号通路的调控作用[J].眼科新进展,2018,38(11):1024.[doi:10.13389/j.cnki.rao.2018.0241]
　REN Run,CAI Ming-Gao,HUO Ming.IGF-1R gene expression inhibits the proliferation and promotes apoptosis of choroidal melanoma through inhibition of STAT3 signaling pathway[J].Recent Advances in Ophthalmology,2018,38(4):1024.[doi:10.13389/j.cnki.rao.2018.0241]
[5]燕玉清,赵红.脉络膜黑色素瘤的病理特点与预后[J].眼科新进展,2019,39(1):075.[doi:10.13389/j.cnki.rao.2019.0017]
　YAN Yu-Qing,ZHAO Hong.The pathological characteristics and prognosis of choroid melanoma[J].Recent Advances in Ophthalmology,2019,39(4):075.[doi:10.13389/j.cnki.rao.2019.0017]
[6]方健文,袁晴,邵毅.人源性肿瘤异种移植模型在眼科的应用进展[J].眼科新进展,2019,39(7):695.[doi:10.13389/j.cnki.rao.2019.0160]
　FANG Jian-Wen,YUAN Qing,SHAO Yi.Application progress of patient-derived xenograft model(PDX) in ophthalmology[J].Recent Advances in Ophthalmology,2019,39(4):695.[doi:10.13389/j.cnki.rao.2019.0160]
[7]史梦琳,吴玮琪,罗昊,等.木犀草素对人脉络膜黑色素瘤细胞株C918血管生成拟态形成的影响[J].眼科新进展,2020,40(8):731.[doi:10.13389/j.cnki.rao.2020.0166]
　SHI Menglin,WU Weiqi,LUO Hao,et al.Inhibitory effects of luteolin on vasculogenic mimicry in human choroidal melanoma cell line C918[J].Recent Advances in Ophthalmology,2020,40(4):731.[doi:10.13389/j.cnki.rao.2020.0166]

备注/Memo

备注/Memo:
北航-首医大数据精准医疗高精尖创新中心同仁分中心开放基金项目（编号：BHTR-KFJJ-202017）
更新日期/Last Update: 2023-04-05